TRIAL DETAIL
Study of XL820 Given Orally Daily to Subjects With Solid Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Study of XL820 Given Orally Daily to Subjects With Solid Tumors |
|||
NCT#: |
||||
Conditions: |
Cancer |
|||
Status: |
Completed |
|||
Phase: |
1 |
Start Date 07/01/2006 |
Age of Trial (yrs) 17.8 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor |
|||
Strategy: |
Block KIT |
|||
Trial Type: |
GIST not specified. GIST patients known to be enrolled. |
|||
Other Protocol IDs: |
||||
Sponsor: |
||||
Patient Contact: |
||||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
2 sites recruiting. Lookup NCT00350831. If using clinicaltrials.gov use 'Focused Search' and 'NCT or Study ID' field. If using cancer .gov use 'Advanced Search' and enter NCT # in 'Protocol ID' field We understand that the phase II trial for GIST has been "withdrawn". |
|||
Trial Links |
Trial Results |
Drug Information |
| The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
195 Little Albany St. |
New Brunswick |
NJ |
08903 |
USA |
|
7979 Wurzbach Rd. |
San Antonio |
TX |
78229 |
USA |